WORCESTER, Mass., April 1, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today that it has signed definitive agreements for the issuance of 8% Secured Convertible Notes and Warrants in a private placement with existing institutional investors for aggregate gross proceeds to Generex of $20,650,000. Generex expects to use the proceeds for working capital purposes, including undertaking global Phase III clinical trials of Generex Oral-lyn at sites in the United States, Canada, and Europe.
